Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
EDAP 
EDAP TMS SA (EDAP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: EDAP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -19.72% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 73.29M USD | Price to earnings Ratio - | 1Y Target Price 10.5 |
Price to earnings Ratio - | 1Y Target Price 10.5 | ||
Volume (30-day avg) 142267 | Beta 0.37 | 52 Weeks Range 1.85 - 8.50 | Updated Date 04/2/2025 |
52 Weeks Range 1.85 - 8.50 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.55 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-27 | When - | Estimate -0.1095 | Actual -0.0539 |
Profitability
Profit Margin -29.66% | Operating Margin (TTM) -18.4% |
Management Effectiveness
Return on Assets (TTM) -14.45% | Return on Equity (TTM) -38.88% |
Valuation
Trailing PE - | Forward PE 38.02 | Enterprise Value 56062131 | Price to Sales(TTM) 1.14 |
Enterprise Value 56062131 | Price to Sales(TTM) 1.14 | ||
Enterprise Value to Revenue 0.81 | Enterprise Value to EBITDA 1165.78 | Shares Outstanding 37392100 | Shares Floating 30010083 |
Shares Outstanding 37392100 | Shares Floating 30010083 | ||
Percent Insiders - | Percent Institutions 41.15 |
Analyst Ratings
Rating 4.33 | Target Price 10.67 | Buy 2 | Strong Buy 1 |
Buy 2 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
EDAP TMS SA
Company Overview
History and Background
EDAP TMS S.A. was founded in 1979. It is a global medical technology company focused on urology. Initially focused on lithotripsy, it expanded into High-Intensity Focused Ultrasound (HIFU) for prostate cancer treatment.
Core Business Areas
- HIFU (High-Intensity Focused Ultrasound): Develops, manufactures, and markets minimally invasive HIFU devices for treating localized prostate cancer and other indications. Focal One is their flagship HIFU product.
- Lithotripsy: Offers devices and services for extracorporeal shock wave lithotripsy (ESWL) to treat kidney stones.
Leadership and Structure
Marc Oczachowski serves as the Chief Executive Officer. The company operates with a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- ExactVu Micro-Ultrasound: Provides high-resolution imaging for targeted prostate biopsies, complementing the Focal One. Number of installations in clinics is growing rapidly. Competitors include BK Medical and Philips.
- Focal One HIFU: A robotic HIFU device for precise ablation of prostate cancer. While specific global HIFU market share data is fragmented, EDAP is a significant player, estimating over 60,000 patients treated. Competitors include Profound Medical (PROF) and Sonacare Medical.
- Sonolith i-sys: Lithotripsy system for kidney stone treatment. Lithotripsy is a mature market with established competitors, including Siemens Healthineers and Dornier MedTech. EDAP competes on technology and features.
Market Dynamics
Industry Overview
The medical device industry is characterized by technological innovation, regulatory scrutiny, and increasing demand for minimally invasive procedures. The prostate cancer treatment market is growing due to an aging population and increased awareness.
Positioning
EDAP is positioned as a leader in minimally invasive prostate cancer treatment with its HIFU technology. Their integrated ExactVu micro-ultrasound enhances their offering.
Total Addressable Market (TAM)
The global prostate cancer therapeutics market is projected to reach $13.2 Billion by 2032. EDAP is well-positioned to capture a share of this TAM with its innovative HIFU technology and diagnostics.
Upturn SWOT Analysis
Strengths
- Leading HIFU technology
- Minimally invasive treatment options
- Strong IP portfolio
- Integrated diagnostic and treatment solutions
- Growing adoption of HIFU
Weaknesses
- Relatively small market capitalization
- Concentration on urology
- Regulatory hurdles for new applications
- Dependence on reimbursement approvals
Opportunities
- Expanding HIFU applications beyond prostate cancer
- Geographic expansion, particularly in Asia
- Partnerships with urology practices
- Development of new diagnostic tools
- Increased reimbursement coverage
Threats
- Competition from established medical device companies
- Technological advancements by competitors
- Changes in reimbursement policies
- Economic downturn affecting healthcare spending
- Adverse clinical trial results
Competitors and Market Share
Key Competitors
- PROF
- BK Medical (part of GEHC)
- Siemens Healthineers (SIEGY)
Competitive Landscape
EDAP TMS SA holds a competitive position in the HIFU market due to its technology. Its competitors are other medical device companies focused on urology and cancer treatment. BK Medical and Siemens Healthineers are large competitors in lithotripsy.
Major Acquisitions
Exact Imaging
- Year: 2021
- Acquisition Price (USD millions): 81.1
- Strategic Rationale: Acquisition of Exact Imaging and its ExactVu micro-ultrasound, enhances EDAP's diagnostic capabilities, and integrates well with its HIFU offering for prostate cancer.
Growth Trajectory and Initiatives
Historical Growth: EDAP's growth has been driven by the increasing adoption of HIFU for prostate cancer treatment. Growth has been positive in recent years, driven by adoption of their integrated solutions and expansion into new territories.
Future Projections: Future growth is projected to come from continued adoption of HIFU, expansion into new markets, and development of new applications. Analyst estimates vary but generally project continued revenue growth.
Recent Initiatives: Focusing on commercial partnerships in new regions and advancing clinical trials for new indications.
Summary
EDAP TMS SA is a medical technology company with a focus on urology, specifically prostate cancer. Its strength lies in its HIFU technology. Recent acquistions and positive market trend are working well for the company. Reimbursement challenges and competition from larger players are issues to monitor.
Similar Companies
ISRG
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
PROF
Profound Medical Corp
PROF
Profound Medical Corp
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change rapidly. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About EDAP TMS SA
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1997-07-31 | CEO & Director Mr. Ryan Rhodes | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 310 | Website https://focalone.com |
Full time employees 310 | Website https://focalone.com | ||
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST) segments. The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. The company serves hospitals, urology clinics, and research institutions. EDAP TMS S.A. was incorporated in 1979 and is based in Lyon, France.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.